Diligence memo · auto-generated · as of July 2, 2026
CASI Pharmaceuticals, Inc.
CASI Pharmaceuticals, Inc. looks fair against its niche peers and is active on financing cadence.
Businessfiled
CASI Pharmaceuticals, Inc. operates in Pharmaceuticals, based in BEIJING.
No verified homepage on file yet — operating evidence is limited to the public record.
Capital & rounds (filed)filed
CASI Pharmaceuticals, Inc. has raised $30M in disclosed capital across 4 recorded rounds, aggregated from public filings. Its latest round is modeled as Series A (a $4.0M–$15M round).
Largest single filing: $15M on 2024-06-26.
Most recent recorded round closed around 2026-02-19.
Valuation (modeled)modeled
Provath models CASI Pharmaceuticals, Inc. at approximately $12M (range $5.7M–$18M). This is an algorithmic estimate from round sizes and same-niche peers — not a quoted or reported figure.
Read: Fair. Modeled value is 0.77× the median modeled value of Series A Pharmaceuticals companies in 2025–2027 (37 peers) — value vs value, same stage and era. Within the normal band (77% of peer median) for its niche.
Financing rhythm & timingmixed
Historic cadence: a new round about every 7 months.
Last raise 4 mo ago; this sector typically re-raises about every 13 months.
Raising on or ahead of the sector's normal rhythm.
The last round stepped up 1.0× from the prior — scaling.
Comparablesmixed
Capital scale ranks ahead of 73% of Pharmaceuticals peers (1613 compared).
Modeled value ranks above 21% of those peers.
Closest niche peers: Incannex Healthcare Inc., Retension Pharmaceuticals, Inc., Eikonoklastes Therapeutics, Inc., Phoenicis Therapeutics, Inc., Pharmaceutical Resource Technology, Inc..
Peoplefiled
14 named people on file across officers, directors and signatories.
Risks & flagsmixed
No clearly named CEO/founder/principal in the surfaced records — key-person evidence is thin.